Journal of Chest Surgery

  • 제50권5호
  • /
  • Pages.378-381
  • /
  • 2017
  • /
  • 2765-1606(pISSN)
  • /
  • 2765-1614(eISSN)
대한심장혈관흉부외과학회 (The Korean Society for Thoracic and Cardiovascular Surgery)
권호 표지
DOI QR코드

DOI QR Code

Large Atrial Septal Defect Closure in a Patient with Severe Pulmonary Arterial Hypertension

  • Supomo, Supomo (Thoracic and Cardiovascular Surgery Division, Department of Surgery, Dr. Sardjito General Hospital, Universitas Gadjah Mada) ;
  • Hartopo, Anggoro Budi (Department of Cardiology and Vascular Medicine, Dr. Sardjito General Hospital, Universitas Gadjah Mada) ;
  • Anggrahini, Dyah Wulan (Department of Cardiology and Vascular Medicine, Dr. Sardjito General Hospital, Universitas Gadjah Mada) ;
  • Darmawan, Handy (Thoracic and Cardiovascular Surgery Division, Department of Surgery, Dr. Sardjito General Hospital, Universitas Gadjah Mada) ;
  • Dinarti, Lucia Kris (Department of Cardiology and Vascular Medicine, Dr. Sardjito General Hospital, Universitas Gadjah Mada)
  • 투고 : 2017.04.12
  • 심사 : 2017.06.13
  • 발행 : 2017.10.05
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Patients with an atrial septal defect (ASD) and severe pulmonary arterial hypertension (PAH) are considered ineligible for defect closure surgery because of the risk of right ventricular decompensation and death after the operation. We report the case of a patient with large ASD and severe PAH who was able to undergo defect closure surgery successfully following long-term use of combined oral sildenafil and beraprost.

키워드

참고문헌

  1. D'Alto M, Mahadevan VS. Pulmonary arterial hypertension associated with congenital heart disease. Eur Respir Rev 2012;21:328-37. https://doi.org/10.1183/09059180.00004712
  2. Oliveira EC, Amaral CF, Moura MA, Campos FT, Pauperio HM. Testing pulmonary vasoreactivity. J Bras Pneumol 2008;34:838-44. https://doi.org/10.1590/S1806-37132008001000013
  3. Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med 2010;104:481-96. https://doi.org/10.1016/j.rmed.2009.11.015
  4. Schwerzmann M, Zafar M, McLaughlin PR, Chamberlain DW, Webb G, Granton J. Atrial septal defect closure in a patient with “irreversible” pulmonary hypertensive arteriopathy. Int J Cardiol 2006;110:104-7. https://doi.org/10.1016/j.ijcard.2005.05.062
  5. Jung IH, Lee SY, Lee SJ, et al. Device closure of a large atrial septal defect in a patient with severe pulmonary arterial hypertension after 1 year use of an oral endothelin receptor antagonist. J Cardiovasc Ultrasound 2013;21:140-4. https://doi.org/10.4250/jcu.2013.21.3.140
  6. Ryerson CJ, Nayar S, Swiston JR, Sin DD. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res 2010;11:12. https://doi.org/10.1186/1465-9921-11-12
  7. Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag 2006;2:411-22. https://doi.org/10.2147/vhrm.2006.2.4.411
  8. Casanova C, Celli BR, Barria P, et al. The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur Respir J 2011;37:150-6. https://doi.org/10.1183/09031936.00194909

피인용 문헌

  1. Pulmonary vascular resistance index: Getting the units right and why it matters vol.42, pp.3, 2017, https://doi.org/10.1002/clc.23151
  2. The screening of congenital heart disease by cardiac auscultation and 12-lead electrocardiogram among Indonesian elementary school students vol.31, pp.2, 2021, https://doi.org/10.1017/s1047951120003881